Abstract
Introduction: Liver cancer is one of the leading causes of cancer related mortality worldwide. It is often diagnosed in advanced stages when treatment options remain limited. Novel diagnostic markers and therapies are therefore urgently needed. The absence of reliable mouse models has been a major limitation in the study of advanced, metastatic liver cancer in the past. Here, we present a novel genetically engineered mouse model of primary liver cancer. In this model, activation of oncogenic Kras together with functional inactivation of the tumor suppressor proteins RB and p53 mimics molecular events that occur in the majority of human liver cancer and leads to rapid formation of hepatic tumors with extrahepatic metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
